Rapid access to innovative medicinal products while ensuring relevant health technology assessment. Position of the French National Authority for Health.

Authors :: Vanier A
Fernandez J
Kelley S
Alter L
Semenzato P
Alberti C
Chevret S
Costagliola D
Cucherat M
Falissard B
Gueyffier F
Lambert J
Lengliné E
Locher C
Naudet F
Porcher R
Thiébaut R
Vray M
Zohar S
Cochat P
Le Guludec D
Source :: BMJ evidence-based medicine [BMJ Evid Based Med] 2024 Jan 19; Vol. 29 (1), pp. 1-5. Date of Electronic Publication: 2024 Jan 19.
Publication Year :: 2024
Abstract: Competing Interests: Competing interests: DC reports an HIV grant from Janssen (2019-2020), personal fees from Gilead (2020) and Pfizer (2022) for lectures outside the submitted work. RT has been the coordinator of the IMI2 EBOVAC2 project in collaboration with Janssen (2014-2021). Other authors have no competing interests to disclose.

Full Text Access

Tools